Oxford Biomedica snags manufacturing equipment to ramp up production of COVID-19 vaccine

In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca's manufacturing partners has struck a deal for new equipment.

Oxford Biomedica has inked a five-year deal with the U.K.'s Vaccines Manufacturing and Research Institute (VMRI) to build out the CDMO's Oxbox facility to help produce doses of the university's adenovirus-based COVID-19 vaccine.